An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

Type of Cancer
Breast Oncology

Site
Howell

Sponsor
PUMA

Protocol Number
PUMA-NER-1301

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combina